Negev Capital
VC Fund
Grand Cayman, Cayman Islands
Negev Capital is a psychedelic medical intervention investment fund with assets of USD$21+ million. We invest in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. We aim to support those early stage companies in need of capital that promote the thoughtful, responsible, and therapeutic use of psychedelicinterventions for neuropsychiatric disorders; as well as those who have excellent management and science teams, and robust IP. Negev believes that psychedelic medications will be not only disruptive to the practice of psychiatry but hold the potential to reduce enormous amounts of human suffering, and is committed to helping the field mature, and further promote ways for these treatments to reach all of those in need.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Negev Capital invests in
Stages Negev Capital invests in
Countries Negev Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 10 (63%)
- Health Care 8 (50%)
- Medical 4 (25%)
- Pharmaceutical 4 (25%)
- Therapeutics 3 (19%)
Stage
- Seed 5 (31%)
- Post-IPO Equity 3 (19%)
- Series A 2 (13%)
- Series B 2 (13%)
- Funding Round 1 (6%)
Country
- United States 7 (44%)
- Canada 5 (31%)
- United Kingdom 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ken Belotsky
Partner
|
Partner | Total investments: 5 | Find email | |
Vadim E. Uzberg
Partner
|
Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Filament Health
|
Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods. | $639.3K / Post-IPO Equity / Apr 03, 2025 | |
|
Filament Health
|
Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods. | $1.7M / Post-IPO Equity / Jun 03, 2024 | |
|
Filament Health
|
Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods. | $1.8M / Post-IPO Equity / Jul 19, 2023 | |
Gilgamesh Pharmaceuticals
|
Gilgamesh Pharmaceuticals focuses on developing therapeutics that target neuropsychiatric and central nervous system conditions using small molecules derived from research on psychedelic compounds. The company designs and tests compounds that aim to modulate brain pathways involved in mental health disorders while reducing hallucinogenic effects.Its pipeline includes drug candidates intended for conditions such as depression, anxiety, and substance use disorders. Gilgamesh Pharmaceuticals conducts preclinical and clinical studies to evaluate the safety, dosing, and efficacy of its compounds. The company integrates medicinal chemistry, neuroscience, and clinical research to support drug development and regulatory progression. | $39M / Series B / Dec 15, 2022 | |
Betterlife Pharma
|
BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage theimmune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer. | $474K / Post-IPO Equity / Dec 07, 2022 | |
Xylo Bio
|
Xylo Bio is a drug development company that focuses on next-generation psychedelics. With psychedelic molecules as the starting point, our goal is to develop medicines that are widely available as improved treatments to currently available SSRI medications. | $3.2M / Seed / Oct 27, 2022 | |
|
Filament Health
|
Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods. | $2.5M / Post-IPO Equity / Jun 30, 2022 | |
Reset Pharmaceuticals
|
Reset Pharma is a biotechnology company that focuses on the development and commercialization of novel psychedelic treatments for patients with life-threatening illnesses, including cancer. Its program focuses on psilocybin with psychotherapy for patients with cancer-related demoralization, anxiety, and depression. | $11.1M / Series A / Feb 16, 2022 | |
Mindstate Design Labs
|
Mindstate Design Labs is a clinical-stage AI neuroengineering platform developing novel psychoactive drug classes for psychiatric disease indications. The company's Osmanthus ensemble of AI models maps the molecular biology of human emotional and cognitive states by integrating the world’s largest datasets of psychoactive pharmacology andsubjective experience. Mindstate's lead program MSD-001 received FDA and EMA approval for Phase I human trials in 2024.Mindstate Design Labs is a Y Combinator company backed by Initialized Capital and other top-tier investors including the founders of OpenAI, Neuralink, Coinbase, Instacart, AngelList, Twitch, and IVADO. The company was founded by biotech venture investor & serial operator Dillan DiNardo and by computer scientist & evolutionary biologist Dr. Thomas Ray, who is famous for instantiating biological phenomena in emergent machine learning systems. | $11.5M / Seed / Feb 10, 2022 | |
Clairvoyant Therapeutics
|
Clairvoyant Therapeutics is a biotechnology company changing the face of psychedelic therapy with a speed-to-market clinical strategy. | $1.8M / Seed / Nov 30, 2021 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Negev Capital invest in?
Negev Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Post-IPO Equity stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Negev Capital?
Public channels for Negev Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Negev Capital?
The team at Negev Capital includes Ken Belotsky (Partner) and Vadim E. Uzberg (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
